LAWSUIT ALERT: Investors in Aardvark Therapeutics, Inc. (NASDAQ:AARD) shares should contact the Shareholders Foundation

LAWSUIT ALERT: Investors in Aardvark Therapeutics, Inc. (NASDAQ:AARD) shares should contact the Shareholders Foundation

Tuesday, 15 September 2026 09:45 AM

Topic: 

Class Action

A lawsuit was filed for certain investors in Aardvark Therapeutics, Inc. (NASDAQ:AARD). NASDAQ:AARD investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.

SAN DIEGO, CA / ACCESS Newswire / September 15, 2026 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Aardvark Therapeutics, Inc. (NASDAQ:AARD).

Investors, who purchased shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD), have certain options and there are short and strict deadlines running. Deadline: October 31, 2026. NASDAQ:AARD investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.

On August 14, 2024, an investor in NASDAQ:AARD filed lawsuit against Aardvark Therapeutics, Inc over alleged securities laws violations.

The lawsuit seeks to recover losses for certain investors.

The plaintiff alleges that the Offering Documents from the Company's February 13, 2025 initial public offer ("IPO") were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, the plaintiff alleges that, between February 13, 2025 and May 14, 2026, the defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.

More specifically, the plaintiff claims that the Offering Documents and the Defendants made false and/or misleading statements and/or failed to disclose that ARD-101 was less safe than the Defendants had led investors to believe, that accordingly, ARD-101's clinical, regulatory, and commercial prospects were overstated, and that as a result, the Defendants' public statements were materially false and misleading at all relevant times.

Those who purchased NASDAQ:AARD shares should contact the Shareholders Foundation, Inc.

CONTACT:

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
[email protected]
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

SOURCE: Shareholders Foundation, Inc.